News

CompleteSpend is a compliance reporting system that collects, aggregates, standardizes and reports spend data based on current state and pending federal regulations. HMS and Alanda combinedly offer an

The formulations facility will produce 3 billion tablets and capsules per annum, which will boost the company’s formulation capacity to nearly10 billion tablets. Torrent’s domestic formulations business grew

The transaction will enhance Novartis’s tools and services that aim to improve health outcomes for patients by advancing the ability to define and monitor individualized treatment programs. Under

Senesco was previously granted orphan drug status for SNS01-T. Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard

The BRF113683 Phase III study compares GSK’436, a BRAF inhibitor, to dacarbazine (DTIC) in previously untreated patients with BRAF V600 mutated advanced or metastatic melanoma. The METRIC study

The trial has already recruited 240-patients. The only aspect of the trial that stopped for a period of time was the enrollment of additional new patients beyond the

The pivotal Phase 3 clinical trial is designed as an outpatient study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DR Cysteamine dosed every 12 hours

Developed by Merz Pharmaceuticals, Memary is an N-methyl-D-aspartate (NMDA) receptor antagonist which has been approved by European EMEA in 2002 and by the US Food and Drug Administration

Fampyra 10mg tablets are prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine or 4-AP). Biogen Idec Neurology Research & Development head Alfred Sandrock said tens of